Three Part Question
In [children with acute asthma] does administration of a bronchodilator [by nebuliser or spacer device] best [decrease admission rate and improve airway function].
A seven year old child with a known history of asthma presents with a 24h history of exacerbation of wheeze. He has been using his salbutamol inhaler with little benefit. You prescribe a ß-agonist by nebuliser but wonder if it would have been cheaper and more effective to administer this drug via a spacer (holding chamber).
Medline 1966 to March Week 4 2006
Embase 1980- 2006 week 13, CINAHL 1982 to March Week 4 2006
The Cochrane Library Issue 1 2006
Medline: [exp asthma OR asthma.mp OR bronchodilator.mp OR exp bronchodilator agents OR exp adrenergic beta-agonists OR beta-agonist.mp OR exp receptors, adrenergic, beta] AND [exp aerosols OR exp "nebulizers and vapourisers" OR exp cholinergic antagonists OR nebuliser.mp OR spacer.mp OR administrat$ OR holding chamber$.mp] AND [acute.mp OR exp acute disease] AND [BestBETs paediatric filter] LIMIT to human and English language
Embase & Cinahl: [asthma.mp OR exp extrinsic asthma OR exp asthma OR wheez$.mp OR bronchodilatOR.mp OR bronchodilating agent OR salbutamol OR salbutamol.mp OR exp salbutamol sulfate OR albuterol.mp OR exp terbutaline sulfate OR exp terbutaline OR terbutaline.mp OR isoproterenol.mp OR exp isoprenaline OR beta-agonist.mp. OR exp beta adrenergic receptor stimulating agent] AND [exp aerosol OR aerosol$.mp OR nebuliser$.mp OR exp nebulizer OR exp medical nebulizer OR nebulizer$.mp OR vaporizer$.mp OR exp vaporizer OR exp inhalational drug administration OR spacer.mp OR exp inhalation spacer OR exp beta adrenergic receptor stimulating agent OR exp drug delivery system OR holding chamber.mp OR exp metered dose inhaler] AND [adult children.mp OR exp adult child OR exp infant OR preschool child OR newborn OR minors.mp OR exp juvenile OR adolescent OR youth.mp OR pediatrics.mp OR exp pediatrics OR child OR paediatric$.mp OR pediatric$.mp OR perinat$.mp OR neonat$.mp OR newborn infan$.mp OR bab$.mp OR toddler$.mp OR boy$.mp OR girl$.mp OR kid$.mp OR schoolage.mp OR underage.mp OR teen$.mp OR offspring.mp OR youth$.mp OR pubescen$.mp OR adolescen$.mp] AND [exp acute drug administration OR acute.mp OR exp acute disease] LIMIT to human and English language.
Cochrane: [Child [MeSH] AND holding chamber [All fields]] OR [Inhalation spacers [MeSH]] 31 articles
1456 papers found including one systematic review and one systematic review with meta-analysis. A further RCT was found that was not mentioned in either review and one RCT had been published subsequent to both reviews.
|Author, date and country
||Study type (level of evidence)
|Cates CJ, Bara A, Crilly JA, Rowe BH|
|Adults and children (but not infants) with acute asthma presenting for medical assistance in the community or hospital emergency department. Included studies on patients with asthma and COPD as long as separate results could be obtained for asthma patients. Randomised to holding chambers (spacers) vs. nebulisers.||Review of randomised controlled trials. 28 trials involving 1260 children over the age of 2y.||Hospital admission rate.||No significant difference on basis of drug administration. RR 0.65; 95% CI:0.56 to 1.38||Review of adults and children over 2y of age but results and findings given separately.|
|Time spent in Emergency Department||Less time in spacer group.Weighted mean difference -0.47 hours (95% CI -0.58 to -0.37)|
|Peak flow & FEV1 at 30min and end of study||No significant difference shown.|
|Pulse rate.||Lower in spacer group. WMD= -7.59% baseline, 95% CI -9.94 to -5.24%|
|Review of 6 studies giving a total of 491 children between 1 and 60 months of age presenting with an acute exacerbation of wheezing or asthma. Randomized to spacer vs. nebuliser for administration of bronchodilators.||Sytematic review with meta-analysis.||Admission rate||Lower in spacer group. Odds Ratio 0.42, 95% CI 0.24-0.72. P=0.002. NNT=10.||Only six studies involved but all of reasonable quality.|
|Clinical severity score||Lower in spacer group. Standardised Mean Difference= -0.44, 95% CI -0.68 to -0.20, P=0.0003|
|Schuh S et al|
|90 children between 5 and 17y presenting to the Emergency Department with an exacerbation of asthma and a FEV1 between 50 and 79% of the predicted value for that child. Exclusion criteria included first presentation with wheeze and use of albuterol (salbutamol) within 4h prior to presentation. Randomized to low dose via spacer, weight determined dose by spacer or weight determined dose by nebuliser.||Single-dose, double-blinded, randomized, triple-dummy controlled trial with 3 treatment arms.||Difference of percentage change in FEV1 after treatment||No significant difference on basis of drug administration.||Primary outcome was difference in mean improvement of FEV1 following treatment. Not clear where predicted FEV1 values derived from. Study powered to find 8% or greater difference between groups, not powered to find differences in other outcomes such as admission rate or relapse rate. Children with very mild or moderate to severe asthma excluded. Children presenting with first episode of wheeze excluded.|
|Admission rate||3 children in low dose group, 1 in high dose group and 2 in the nebuliser group admitted.|
|Heart rate following treatment.||Significantly higher in nebuliser group. P=0.005|
|Relapse requiring unscheduled medical visit||1 in the low dose group, 2 in the high dose group and 2 in the nebuliser group.|
|Deerojanawong J et al|
|47 children under the age of 5y presenting with acute wheeze randomized to metered dose inhaler-spacer vs. jet nebuliser for salbutamol administration.||Prospective, randomized, double-blind, placebo-controlled trial.||Change in ratio of Volume to Peak Tidal Expiratory Flow against Time to Peak Tidal Expiratory Flow||No significant difference on basis of drug administration. P=0.004.||Although other studies have validated VPEF/TPEF as a useful measurement in estimating obstructive airway disease in young children the clinical outcomes of the children in this study are not documented.|
|Reduction in resistance of respiratory system||No significant difference. P=0.025.|
|Change in heart rate||Increased in nebuliser group. P=0.004.|
Nebulisers are commonly used in the emergency setting for the treatment of acute asthma in children despite recent research suggesting that administration by a holding chamber or spacer is at least as effective. These review articles and the two papers not included in these articles all concur with this view and tend to show a slight improvement in out-come with use of a spacer device. This research is limited to patients with moderate or severe asthma as patients with life-threatening asthma have been excluded from all of the studies. Spacer devices are faster and easier to use and may also be cheaper than nebulisers. The cost is less of a factor in patients attending hospital compared with community use due to availability of piped oxygen. They also have less maintenance involved and reduce the potential risk of cross infection.
Clinical Bottom Line
In most cases where a child presents with moderate to severe asthma beta-2-agonists could be delivered via a spacer device in place of a nebuliser.
Level of Evidence
Level 1 - Recent well-done systematic review was considered or a study of high quality is available.
- Cates CJ, Bara A, Crilly JA, Rowe BH Holding chambers versus nebulisers for beta-agonist treatment of acute asthma (Review) The Cochrane Database of Systematic Reviews 2003, Issue 2. Art No.: CD000052. DOI: 10:1002/14651858.CD000052
- Castro-Rodriguez JA, Rodrigo GJ ß-Agonists Through Metered-Dose Inhaler with Valved Holding Chamber Versus Nebulizer for Acute Exacerbations of Wheezing or Asthma in Children Under 5 Years of Age The Journal of Pediatrics Aug 2004; 172-177
- Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ Comparison of Albuterol Delivered by a Metered Dose Inhaler with a Spacer Versus a Nebulizer in Children With Mild Acute Asthma The Journal of Pediatrics 135(1); 22-27
- Deerojanawong J, Manuyakorn W, Prapphal N, Harnruthakorn C, Sritippayawan S, Samransamruajkit R Randomized Controlled Trial of Salbutamol Aerosol Therapy Via Metered Dose Inhaler-Spacer vs. Jet Nebulizer in Young Children With Wheezing Pediatric Pulmonology 2005; 39:466-472